Stock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced

Stock Track

2025/09/30

REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.

The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.

Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1167520313"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167520313\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167520313?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167520313","market":"sg","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced","media":"Stock Track","content":"<p>REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.</p>\n\n<p>The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.</p>\n\n<p>Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-09-30 11:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.</p>\n\n<p>The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.</p>\n\n<p>Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"榮昌生物","start_time":0,"source_url":"","article_id":"1167520313","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167520313","pubTimestamp":1759202540,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|REMEGEN飙升7.41%，眼科药物申报审批和ESMO演示公布","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.\nThe primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.\nAdding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}